Editorial Staff

Moving the Needle on Healthcare Cost Containment & Reform

/0 Comments/in , , , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Today, Pioneer Institute submitted recommendations to the Commonwealth of Massachusetts’ Special Senate Committee on Health Care Cost Containment and Reform. Pioneer applauds provisions of the proposed legislation that would reduce emergency room use and re-admissions, expand scope of practice, and embrace telemedicine. The Committee should also be commended for looking to other states’ accomplishments in this area.

But the current bill raises some concerns. In some instances, we believe it diminishes the potential for greater cost savings by adding unnecessary regulatory burdens. The projected savings relative to 2020 spending are quite modest, at less than 0.2 percent. The Medicaid buy-in program as it is presented is a radical change from the existing program structure – it will require more elaboration and analysis, as it is unclear what the impact of this proposal will be on MassHealth and providers across the Commonwealth. Pioneer also has concerns that the bill could lead to harmful unintended consequences, such as the collapse of the merged private insurance market. We hope the Legislature addresses these issues, but this bill starts an important healthcare cost conversation in Massachusetts, and we commend the Senate for taking the lead in this effort. Read Pioneer’s full letter to the Committee.

Get Updates On Our Healthcare Research and Events!

Related Research

University Science Research Is Under Threat

The Biden administration's formation of a working group to “develop a framework for the implementation of the march-in provision of the Bayh-Dole Act" could have serious adverse consequences for university research and biopharmaceutical innovation. It represents a particularly dangerous threat to the thriving life sciences cluster in Greater Boston.

Opinion: Legislature should act on bill to limit out-of-pocket drug costs

S. 609, a bill that would limit out-of-pocket costs for patients paying for prescription drugs, is a clear step in the right direction. Massachusetts should join 16 other states that have passed similar bills to protect patients.

Healthcare: Suffolk County’s Biggest Driver for Labor and Employment

Suffolk County employment and labor trends have seen steady growth over the past 15 years. The rise of establishments and employment in the health care sector has directly contributed to these trends. Suffolk County has now surpassed Worcester and Essex counties in labor force and employment numbers.

Opinion: Drug patents aren’t a ‘necessary evil.’ They save lives.

Drug patents are one of the most important public policy innovations in all of human history, and a boon to patients awaiting cures. Inventions only come when inventors are rewarded, not punished. Patents are not a “necessary evil.”

Study: High List Prices and Deep Discounts for Prescription Drugs Hurt Poor and Sick Patients

A new Pioneer Institute study illustrates how the current system of drug pricing and discounts leads to patients with challenging diseases being charged huge out-of-pocket sums to keep other premiums low, effectively imposing financial penalties on the sick to protect the healthy and wealthy.

Massachusetts’ Misguided Middle-Class Health Insurance Subsidy Expansion

A proposal on Beacon Hill to expand insurance subsidies up to 500 percent of the federal poverty level, could push the small business insurance market into a death spiral, without reducing the number of uninsured and hurting those with preexisting conditions.

Study: Massachusetts Should Join 45 States and Allow Prescribers to Dispense Medications

A Pioneer Institute study shows that middlemen—commercial pharmacies and pharmacy benefit managers—add substantial costs over wholesale prices. Allowing prescribers to dispense routine drugs would save consumers money without compromising safety.

A Federal Drug Discount Program for the Wealthy

The combination of legal disputes, a growing data repository and investigative reports have necessarily put the 340B Drug Pricing Program under the microscope. Combined with the fact that the policy lacks transparency, 340B has spiraled out of control to the point that no policymaker can ignore the need to look closer.

Sunshine Week 2023: Shining Light on the Workings of Government

Pioneer Institute is proud to join with the media and others—including The Boston Herald, The Boston Globe, CommonWealth Magazine, Common Cause, and the ACLU—in marking Sunshine Week, March 12-18.

As COVID-19 Emergencies Ease, Some Progress on Telehealth Rules

A new report from Reason Foundation, Cicero Institute and Pioneer Institute rates every state’s telehealth policy for patient access and ease of providing virtual care. The report highlights telehealth policy best practices for states.

First-of-Its-Kind Interactive Mapping Tool Reveals Extent of For-Profit Entities Benefitting from the 340B Drug Pricing Program

Today, Pioneer Institute released a first-of-its-kind, 50-state mapping tool and database highlighting the troubling way in which hospitals and covered entities leverage unlimited pharmacy contracts under the 340B Drug Pricing Program.

Survey Finds Spotty Compliance Among Hospitals with Federal Price Transparency Law

A 2019 federal law requires hospitals to make prices for 300 shoppable services available online in a “consumer-friendly format,” but a Pioneer Institute survey of 19 hospitals finds that information on discounted cash prices—the price most likely to be charged to consumers paying out of pocket—was unavailable at seven of those hospitals.

Harvard research points to ending drug cost help

A common grievance about Harvard is that the university is out of touch with the concerns of everyday Americans. This perception is confirmed by recent research from Harvard Business School that contends patients should be denied assistance that helps them afford their prescription drugs. The Harvard study argues that in order to control drug prices, the government should deny patients’ access to copay assistance programs offered by drug manufacturers. It flies in the face of federal and state efforts to protect the value of such assistance programs for patients and ignores basic facts about how and when patients use copay assistance to access their medications.

Is CHIA’s Drug Cost Data Reliable?

Earlier this year, the Center for Health Information and Analysis (CHIA) released its Annual Report on the Performance of the Massachusetts Health Care System for 2020.  The Massachusetts Legislature relies on CHIA data when considering bills to regulate drug costs and prices. The advocacy group Health Care for All reported that CHIA data showed prescription drug spending grew by 7.7 percent in 2020, more than twice the benchmark - but the most reliable data on prescription drugs indicates that spending in 2020 was essentially flat. 

Is this PBM tactic blocking healthcare access?

Utilization Management (UM) was originally a strategy designed to improve the safety, quality, and cost-effectiveness of physician prescribing. However, UM has grown exponentially over the last decade, becoming more a tactic for Pharmacy Benefit Managers (PBMs) to manage costs to benefit their bottom line.

The Realities Behind US Healthcare Spending

Healthcare policy is an all-encompassing term. It plays a role in every individual’s life; how it is curated, developed, and maintained has a significant long-term impact on the quality of life of any given community. It is critical that policymakers consistently adapt and amend healthcare policies in the ever-changing global pricing and affordability environment while providing funding support for optimal quality of care.

Cures for Patients, Not Health Plan Profits, Make Drugs Valuable

To the astonishment of many observers, the Institute for Clinical and Economic Review (ICER) recently concluded that a $2.1 million gene therapy for a life-threatening blood disorder called beta thalassemia, is priced cost-effectively. The surprise was especially pleasant, given that ICER’s methodology had, in the past, displayed bias against rare disease treatments and undervalued the lives of people living with disabilities.

Healthcare dominates the job market.

0 Comments
/
Healthcare and social assistance are among the most important…